Pulmonx (LUNG) Competitors

Pulmonx logo
$2.73 -0.07 (-2.50%)
Closing price 04:00 PM Eastern
Extended Trading
$2.73 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LUNG vs. NPCE, SI, BWAY, CARL, and ARAY

Should you buy Pulmonx stock or one of its competitors? Pulmonx's main competitors and comparable companies include NeuroPace (NPCE), Shoulder Innovations (SI), Brainsway (BWAY), Carlsmed (CARL), and Accuray (ARAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulmonx compare to NeuroPace?

Pulmonx (NASDAQ:LUNG) and NeuroPace (NASDAQ:NPCE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 19.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, NeuroPace had 37 more articles in the media than Pulmonx. MarketBeat recorded 38 mentions for NeuroPace and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.61 beat NeuroPace's score of -0.24 indicating that Pulmonx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulmonx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NeuroPace
3 Very Positive mention(s)
8 Positive mention(s)
7 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)
Neutral

NeuroPace has higher revenue and earnings than Pulmonx. NeuroPace is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$90.50M1.31-$54M-$1.01N/A
NeuroPace$99.99M2.83-$21.47M-$0.56N/A

Pulmonx has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

NeuroPace has a net margin of -20.00% compared to Pulmonx's net margin of -47.93%. Pulmonx's return on equity of -98.23% beat NeuroPace's return on equity.

Company Net Margins Return on Equity Return on Assets
Pulmonx-47.93% -98.23% -35.89%
NeuroPace -20.00%-117.31%-16.83%

Pulmonx currently has a consensus price target of $7.67, suggesting a potential upside of 180.83%. NeuroPace has a consensus price target of $13.11, suggesting a potential upside of 59.89%. Given Pulmonx's stronger consensus rating and higher probable upside, research analysts plainly believe Pulmonx is more favorable than NeuroPace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmonx
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
NeuroPace
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.36

Summary

NeuroPace beats Pulmonx on 10 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Shoulder Innovations?

Pulmonx (NASDAQ:LUNG) and Shoulder Innovations (NYSE:SI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Pulmonx has a net margin of -47.93% compared to Shoulder Innovations' net margin of -51.72%. Shoulder Innovations' return on equity of -25.37% beat Pulmonx's return on equity.

Company Net Margins Return on Equity Return on Assets
Pulmonx-47.93% -98.23% -35.89%
Shoulder Innovations -51.72%-25.37%-20.87%

Pulmonx currently has a consensus price target of $7.67, indicating a potential upside of 180.83%. Shoulder Innovations has a consensus price target of $25.75, indicating a potential upside of 25.51%. Given Pulmonx's higher probable upside, equities research analysts clearly believe Pulmonx is more favorable than Shoulder Innovations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmonx
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Shoulder Innovations
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

91.0% of Pulmonx shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 29.0% of Shoulder Innovations shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Shoulder Innovations had 2 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for Shoulder Innovations and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.61 beat Shoulder Innovations' score of 0.49 indicating that Pulmonx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulmonx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Shoulder Innovations
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pulmonx has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Shoulder Innovations has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

Shoulder Innovations has lower revenue, but higher earnings than Pulmonx. Shoulder Innovations is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$90.50M1.31-$54M-$1.01N/A
Shoulder Innovations$47.32M9.07-$40.36M-$1.62N/A

Summary

Shoulder Innovations beats Pulmonx on 8 of the 15 factors compared between the two stocks.

How does Pulmonx compare to Brainsway?

Pulmonx (NASDAQ:LUNG) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Pulmonx has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Brainsway has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Brainsway has a net margin of 15.54% compared to Pulmonx's net margin of -47.93%. Brainsway's return on equity of 13.09% beat Pulmonx's return on equity.

Company Net Margins Return on Equity Return on Assets
Pulmonx-47.93% -98.23% -35.89%
Brainsway 15.54%13.09%8.50%

In the previous week, Brainsway had 3 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for Brainsway and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.61 beat Brainsway's score of -0.05 indicating that Pulmonx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulmonx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Brainsway
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pulmonx presently has a consensus target price of $7.67, indicating a potential upside of 180.83%. Brainsway has a consensus target price of $18.20, indicating a potential upside of 99.78%. Given Pulmonx's higher possible upside, equities research analysts plainly believe Pulmonx is more favorable than Brainsway.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmonx
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Brainsway
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

Brainsway has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$90.50M1.31-$54M-$1.01N/A
Brainsway$52.22M7.02$7.57M$0.5018.22

Summary

Brainsway beats Pulmonx on 12 of the 16 factors compared between the two stocks.

How does Pulmonx compare to Carlsmed?

Pulmonx (NASDAQ:LUNG) and Carlsmed (NASDAQ:CARL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

91.0% of Pulmonx shares are held by institutional investors. 7.5% of Pulmonx shares are held by insiders. Comparatively, 12.9% of Carlsmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Pulmonx presently has a consensus price target of $7.67, indicating a potential upside of 180.83%. Carlsmed has a consensus price target of $22.00, indicating a potential upside of 24.01%. Given Pulmonx's higher possible upside, equities analysts clearly believe Pulmonx is more favorable than Carlsmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmonx
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Carlsmed
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Pulmonx has a net margin of -47.93% compared to Carlsmed's net margin of -55.82%. Carlsmed's return on equity of -42.42% beat Pulmonx's return on equity.

Company Net Margins Return on Equity Return on Assets
Pulmonx-47.93% -98.23% -35.89%
Carlsmed -55.82%-42.42%-30.87%

In the previous week, Carlsmed had 21 more articles in the media than Pulmonx. MarketBeat recorded 22 mentions for Carlsmed and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.61 beat Carlsmed's score of 0.47 indicating that Pulmonx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulmonx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Carlsmed
5 Very Positive mention(s)
2 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Carlsmed has lower revenue, but higher earnings than Pulmonx. Carlsmed is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$90.50M1.31-$54M-$1.01N/A
Carlsmed$50.51M9.62-$29.63M-$1.48N/A

Pulmonx has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Carlsmed has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

Summary

Carlsmed beats Pulmonx on 8 of the 14 factors compared between the two stocks.

How does Pulmonx compare to Accuray?

Pulmonx (NASDAQ:LUNG) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

In the previous week, Accuray had 2 more articles in the media than Pulmonx. MarketBeat recorded 3 mentions for Accuray and 1 mentions for Pulmonx. Pulmonx's average media sentiment score of 0.61 beat Accuray's score of 0.46 indicating that Pulmonx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulmonx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Accuray
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pulmonx has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Accuray has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Accuray has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$90.50M1.31-$54M-$1.01N/A
Accuray$401.95M0.02-$49.19M-$6.00N/A

91.0% of Pulmonx shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 7.5% of Pulmonx shares are held by company insiders. Comparatively, 3.5% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Pulmonx presently has a consensus target price of $7.67, indicating a potential upside of 180.83%. Given Pulmonx's stronger consensus rating and higher probable upside, equities research analysts plainly believe Pulmonx is more favorable than Accuray.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulmonx
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Accuray
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Accuray has a net margin of -4.41% compared to Pulmonx's net margin of -47.93%. Accuray's return on equity of -35.36% beat Pulmonx's return on equity.

Company Net Margins Return on Equity Return on Assets
Pulmonx-47.93% -98.23% -35.89%
Accuray -4.41%-35.36%-3.88%

Summary

Pulmonx beats Accuray on 8 of the 15 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Sign up to receive the latest news and ratings for LUNG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LUNG vs. The Competition

MetricPulmonxHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$121.94M$5.98B$7.82B$11.74B
Dividend YieldN/A1.68%2.47%4.47%
P/E Ratio-2.7035.3532.7626.82
Price / Sales1.315.398.565.70
Price / CashN/A23.6221.0121.90
Price / Book3.464.174.463.72
Net Income-$54M$143.92M$3.52B$393.10M
7 Day Performance-2.50%-5.00%-5.47%-4.73%
1 Month Performance53.37%-3.68%-4.57%-7.14%
1 Year Performance100.74%-0.46%-1.79%-7.51%

Pulmonx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LUNG
Pulmonx
2.8349 of 5 stars
$2.73
-2.5%
$7.67
+180.8%
+87.9%$121.94M$90.50MN/A296
NPCE
NeuroPace
4.1558 of 5 stars
$13.02
-0.8%
$20.50
+57.5%
-38.4%$446.64M$99.99MN/A220
SI
Shoulder Innovations
2.4486 of 5 stars
$21.07
-1.8%
$25.75
+22.2%
+39.3%$437.53M$47.32MN/A75
BWAY
Brainsway
4.6071 of 5 stars
$10.81
-7.1%
$18.20
+68.4%
+19.2%$435.10M$52.22M24.57129
CARL
Carlsmed
2.0897 of 5 stars
$15.44
-3.8%
$19.50
+26.3%
+32.3%$428.75M$50.51MN/A127

Related Companies and Tools


This page (NASDAQ:LUNG) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners